CA2758041A1 - Process for tumour characteristic and marker set identification, tumour classification and marker sets for cancer - Google Patents

Process for tumour characteristic and marker set identification, tumour classification and marker sets for cancer Download PDF

Info

Publication number
CA2758041A1
CA2758041A1 CA2758041A CA2758041A CA2758041A1 CA 2758041 A1 CA2758041 A1 CA 2758041A1 CA 2758041 A CA2758041 A CA 2758041A CA 2758041 A CA2758041 A CA 2758041A CA 2758041 A1 CA2758041 A1 CA 2758041A1
Authority
CA
Canada
Prior art keywords
gene expression
tumour
sets
cancer
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2758041A
Other languages
English (en)
French (fr)
Inventor
Anne E. G. Lenferink
Jie Li
Maureen D. O'connor-Mccourt
Enrico Purisima
Edwin Wang
Yinghai Deng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council of Canada
Original Assignee
National Research Council of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council of Canada filed Critical National Research Council of Canada
Publication of CA2758041A1 publication Critical patent/CA2758041A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G01N33/57515—
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2758041A 2009-04-16 2010-04-16 Process for tumour characteristic and marker set identification, tumour classification and marker sets for cancer Abandoned CA2758041A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20288109P 2009-04-16 2009-04-16
US61/202,881 2009-04-16
PCT/CA2010/000565 WO2010118520A1 (en) 2009-04-16 2010-04-16 Process for tumour characteristic and marker set identification, tumour classification and marker sets for cancer

Publications (1)

Publication Number Publication Date
CA2758041A1 true CA2758041A1 (en) 2010-10-21

Family

ID=42982085

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2758041A Abandoned CA2758041A1 (en) 2009-04-16 2010-04-16 Process for tumour characteristic and marker set identification, tumour classification and marker sets for cancer

Country Status (7)

Country Link
US (1) US20120040863A1 (enExample)
EP (1) EP2419533A4 (enExample)
JP (2) JP2012525818A (enExample)
CN (3) CN105132544A (enExample)
AU (1) AU2010237568A1 (enExample)
CA (1) CA2758041A1 (enExample)
WO (1) WO2010118520A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2913405B1 (en) 2010-07-27 2016-11-09 Genomic Health, Inc. Method for using gene expression to determine prognosis of prostate cancer
CA2829776A1 (en) * 2011-03-14 2012-09-20 National Research Council Of Canada Prognostic marker sets for prostate cancer
US12130290B2 (en) * 2016-11-29 2024-10-29 Trustees Of Tufts College Compositions and methods for diagnosing breast cancer
WO2018219342A1 (zh) * 2017-06-01 2018-12-06 立森印迹诊断技术有限公司 一种印记基因分级模型和诊断方法及其应用
CN110890128B (zh) * 2018-09-10 2024-02-09 立森印迹诊断技术（无锡）有限公司 一种用于检测皮肤肿瘤良恶性程度的分级模型及其应用
JP7352937B2 (ja) * 2019-07-19 2023-09-29 公立大学法人福島県立医科大学 乳癌のサブタイプを鑑別又は分類するための鑑別マーカー遺伝子セット、方法およびキット
CN115064209B (zh) * 2022-08-17 2022-11-01 普瑞基准科技（北京）有限公司 一种恶性细胞鉴定方法及系统

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7955800B2 (en) * 2002-06-25 2011-06-07 Advpharma Inc. Metastasis-associated gene profiling for identification of tumor tissue, subtyping, and prediction of prognosis of patients
EP1730308A4 (en) * 2004-03-05 2008-10-08 Rosetta Inpharmatics Llc CLASSIFICATION OF BREAST CANCER PATIENTS USING A COMBINATION OF CLINICAL CRITERIA AND INFORMATIVE SKILLS
JP5690039B2 (ja) * 2004-06-04 2015-03-25 バイオセラノスティクス インコーポレイテッドＢｉｏｔｈｅｒａｎｏｓｔｉｃｓ，Ｉｎｃ． 腫瘍の同定
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US20100234292A1 (en) * 2007-04-16 2010-09-16 Ipsogen Methods of assessing a propensity of clinical outcome for a female mammal suffering from breast cancer

Also Published As

Publication number Publication date
US20120040863A1 (en) 2012-02-16
WO2010118520A1 (en) 2010-10-21
CN102421920A (zh) 2012-04-18
EP2419533A1 (en) 2012-02-22
CN105200124A (zh) 2015-12-30
EP2419533A4 (en) 2014-12-31
AU2010237568A1 (en) 2011-11-17
JP2012525818A (ja) 2012-10-25
CN102421920B (zh) 2015-09-30
JP2016073287A (ja) 2016-05-12
CN105132544A (zh) 2015-12-09

Similar Documents

Publication Publication Date Title
CN101932724B (zh) 胃肠癌的增生标签及预后
KR101921945B1 (ko) 폐암 바이오마커 및 그것의 용도
US20140220580A1 (en) Biomarker compositions and methods
US20160041153A1 (en) Biomarker compositions and markers
US20120040863A1 (en) Process for tumour characteristic and marker set identification, tumour classification and marker sets for cancer
US20080182246A1 (en) Methods of predicting distant metastasis of lymph node-negative primary breast cancer using biological pathway gene expression analysis
AU2019250606B2 (en) Improved classification and prognosis of prostate cancer
AU2012294458A1 (en) Biomarker compositions and methods
AU2010242792A1 (en) Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
US20230021094A1 (en) Composition for predicting response to standard preoperative chemoradiation therapy and prognosis following treatment, and method and composition for predicting patients with very unsatisfactory prognoses following standard therapy
BR112016004153A2 (pt) "método para caracterizar uma doença ou distúrbio, kit, composição, método para gerar uma biblioteca de entrada, oligonucleotídeo, pluralidade de oligonucleotídeos e método para identificar um aptâmero
Soldini et al. A new diagnostic algorithm for Burkitt and diffuse large B-cell lymphomas based on the expression of CSE1L and STAT3 and on MYC rearrangement predicts outcome
Deng et al. Multicellular ecotypes shape progression of lung adenocarcinoma from ground-glass opacity toward advanced stages
AU2019201377A1 (en) Proliferation signature and prognosis for gastrointestinal cancer
WO2019229302A1 (en) L1td1 as predictive biomarker of colon cancer
van der Stok et al. mRNA expression profiles of colorectal liver metastases as a novel biomarker for early recurrence after partial hepatectomy
CN113832228A (zh) 生物标志物在预测直肠癌对术前放化疗联合全直肠系膜切除术的敏感性中的应用
US20250270649A1 (en) Biomarker composition for early detection and prognosis prediction of lung adenocarcinoma through aven gene and its associated genes
CN117545856A (zh) 大肠癌及晚期腺瘤的筛查方法及其应用
WO2015181556A1 (en) Pro-angiogenic expression signature

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150121

FZDE Discontinued

Effective date: 20170814